Corzo D.Byrne B.WUH-LIANG HWULeslie N.Mandel H.Nicolino M.2020-12-162020-12-1620080149-2918https://www.scopus.com/inward/record.uri?eid=2-s2.0-40749107445&doi=10.1016%2fS0149-2918%2808%2980023-9&partnerID=40&md5=57ffce76f17230b18c19fe6cd53da13chttps://scholars.lib.ntu.edu.tw/handle/123456789/525981[SDGs]SDG3glucan 1,4 alpha glucosidase; immunoglobulin G antibody; recombinant glucan 1,4 alpha glucosidase; antibody titer; article; artificial ventilation; cardiomyopathy; cause of death; clinical trial; drug effect; drug efficacy; drug infusion; enzyme replacement; glycogen storage disease type 2; human; mortality; prognosis; seroconversion; survival rate; treatment duration; treatment outcomejournal article10.1016/S0149-2918(08)80023-92-s2.0-40749107445